Harrington Heart & Vascular Institute, University Hospitals, Case Western Reserve University, Cleveland, Ohio.
Vascular Medicine Outcomes Program (VAMOS), Division of Cardiology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
Am J Cardiol. 2023 Aug 15;201:166-169. doi: 10.1016/j.amjcard.2023.05.053. Epub 2023 Jun 27.
Women, older adults, and racial/ethnic minorities are differentially affected by lower extremity peripheral artery disease (PAD), yet their representation in randomized controlled trials (RCTs) on which current PAD guidelines are based is not known. We therefore evaluated whether RCTs supporting most recent American Heart Association/American College of Cardiology lower extremity PAD guidelines proportionately represent the spectrum of demographic groups affected by PAD. All PAD-specific RCTs cited in the guidelines were included. From 409 references, 78 RCTs were included, representing 101,359 patients. Pooled proportion of women enrolled was 33% (95% confidence interval 29% to 37%) versus 57.5% in US PAD epidemiologic studies. Pooled mean age of all trial participants was 67.4 ± 0.8 years, in comparison with global estimates of PAD, in which 29.4% of the global population with PAD is >70 years old. Race/ethnicity distribution was reported in 27% of studies (21 of 78). In conclusion, in trials supporting current PAD guidelines, women and older adults patients are underrepresented, and different race and ethnic groups are underreported across the spectrum of studies. Underrepresentation of these groups differentially affected by PAD may limit the generalizability of the evidence supporting PAD guidelines.
女性、老年人和少数族裔在下肢外周动脉疾病(PAD)中受到不同程度的影响,但目前基于 PAD 指南的随机对照试验(RCT)中并未反映出这些人群的代表性。因此,我们评估了支持美国心脏协会/美国心脏病学会最新下肢 PAD 指南的 RCT 是否在一定程度上代表了受 PAD 影响的各种人群的情况。指南中引用的所有特定于 PAD 的 RCT 均被纳入研究。从 409 篇参考文献中,共纳入了 78 项 RCT,涵盖了 101359 名患者。纳入研究的女性比例为 33%(95%置信区间 29%至 37%),而美国 PAD 流行病学研究中的女性比例为 57.5%。所有试验参与者的平均年龄为 67.4 ± 0.8 岁,而全球 PAD 估计中,29.4%的全球 PAD 患者年龄大于 70 岁。有 27%的研究报告了种族/民族分布情况(78 项研究中的 21 项)。总之,在支持当前 PAD 指南的试验中,女性和老年患者的代表性不足,不同种族和民族的代表性不足,且研究范围不同。PAD 对这些人群的不同影响可能会限制支持 PAD 指南的证据的普遍性。